{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:52:31Z","timestamp":1791805951393,"version":"4.3.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007161","name":"Instituto Polit\u00e9cnico Nacional Secretar\u00eda de Investigaci\u00f3n y Posgrado","doi-asserted-by":"publisher","award":["SIP20254031"],"award-info":[{"award-number":["SIP20254031"]}],"id":[{"id":"10.13039\/501100007161","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Secretar\u00eda de Ciencia, Humanidades, Tecnolog\u00eda e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013395","name":"Sistema Nacional de Investigadores","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013395","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["canadianjournalofdiabetes.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Diabetes"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jcjd.2026.01.007","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T07:56:54Z","timestamp":1770364614000},"page":"183-190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Peroxisome Proliferator-activated Receptors in Diabetic Retinopathy: Pathophysiologic Insights and Emerging Pharmacologic Strategies"],"prefix":"10.1016","volume":"50","author":[{"given":"Lorena","family":"Mandujano-Ferrer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Alem\u00e1n-Gonz\u00e1lez-Duhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjd.2026.01.007_bib1","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.3390\/jcm11102761","article-title":"The effect of hyperlipidemia on the course of diabetic retinopathy: Literature review","volume":"11","author":"Bryl","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jcjd.2026.01.007_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jcjd.2026.01.007_bib3","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.3390\/ijms24033024","article-title":"Discovery of novel thiazolidinedione-derivatives with multi-modal antidiabetic activities in vitro and in silico","volume":"24","author":"Arineitwe","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcjd.2026.01.007_bib4","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamaophthalmol.2023.2289","article-title":"Prevalence of diabetic retinopathy in the US in 2021","volume":"141","author":"Lundeen","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjd.2026.01.007_bib5","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/bph.14665","article-title":"Retinal and circulating miRNA expression patterns in diabetic retinopathy: An in silico and in vivo approach","volume":"176","author":"Platania","year":"2019","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jcjd.2026.01.007_bib6","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045: Systematic review and meta-analysis","volume":"128","author":"Teo","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjd.2026.01.007_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e04589","article-title":"Formulation of PPAR-gamma agonist as surface modified PLGA nanoparticles for non-invasive treatment of diabetic retinopathy: In vitro and in vivo evidences","volume":"6","author":"Laddha","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.jcjd.2026.01.007_bib8","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2026.01.007_bib9","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3389\/fendo.2020.00591","article-title":"Endothelial dysfunction in diabetic retinopathy","volume":"11","author":"Gui","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jcjd.2026.01.007_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fcdhc.2024.1319840","article-title":"Associated factors of diabetic retinopathy in type 1 and 2 diabetes in Limpopo province in South Africa","volume":"5","author":"Maluleke","year":"2024","journal-title":"Front Clin Diabetes Healthc"},{"key":"10.1016\/j.jcjd.2026.01.007_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2020.113324","article-title":"Fufang Xueshantong alleviates diabetic retinopathy by activating the PPAR signalling pathway and complement and coagulation cascades","volume":"265","author":"Sun","year":"2021","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.jcjd.2026.01.007_bib12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3892\/ijmm.2021.4908","article-title":"Therapeutic potential of curcumin in diabetic retinopathy","volume":"47","author":"Yang","year":"2021","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.jcjd.2026.01.007_bib13","article-title":"Prevalence, risk factors and burden of diabetic retinopathy in China: A systematic review and meta-analysis","volume":"8","author":"Song","year":"2018","journal-title":"J Glob Health"},{"key":"10.1016\/j.jcjd.2026.01.007_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174032","article-title":"Effect of dual PPAR \u03b1\/\u03b3 agonist saroglitazar on diabetic retinopathy and oxygen-induced retinopathy","volume":"899","author":"Joharapurkar","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jcjd.2026.01.007_bib15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ophtha.2022.07.024","article-title":"Prevalence of diabetic retinopathy in Indigenous and non-Indigenous Australians: A systematic review and meta-analysis","volume":"130","author":"Chia","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjd.2026.01.007_bib16","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jamaophthalmol.2022.0050","article-title":"Global estimates of diabetic retinopathy prevalence and progression in pregnant women with preexisting diabetes: A systematic review and meta-analysis","volume":"140","author":"Widyaputri","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjd.2026.01.007_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.1887","article-title":"Global prevalence of diabetic retinopathy in pediatric type 2 diabetes: A systematic review and meta-analysis","volume":"6","author":"Cioana","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jcjd.2026.01.007_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.620045","article-title":"Emerging roles of dyslipidemia and hyperglycemia in diabetic retinopathy: Molecular mechanisms and clinical perspectives","volume":"12","author":"Rao","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jcjd.2026.01.007_bib19","first-page":"123","article-title":"Clinical staging and progression of diabetic retinopathy: A review","volume":"65","author":"Rao","year":"2021","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.jcjd.2026.01.007_bib20","article-title":"Proliferative diabetic retinopathy: Mechanisms and risk of detachment","volume":"34","author":"Tomita","year":"2020","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jcjd.2026.01.007_bib21","first-page":"491","article-title":"PPAR\u03b3-mediated differences in energy substrate among T2DM patients differing in the stage of diabetic retinopathy","volume":"6","author":"Rykov","year":"2019","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.jcjd.2026.01.007_bib22","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.18632\/aging.202433","article-title":"Association between PPAR-\u03b32 gene polymorphisms and diabetic retinopathy risk: A meta-analysis","volume":"13","author":"Li","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.jcjd.2026.01.007_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.119013","article-title":"Combination therapy with semaglutide and rosiglitazone as a synergistic treatment for diabetic retinopathy in rodent animals","volume":"269","author":"Yang","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.jcjd.2026.01.007_bib24","first-page":"12","article-title":"Diabetic retinopathy: Molecular mechanisms and therapeutic targets beyond glycemic control","volume":"72","author":"Rosenfeld","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.jcjd.2026.01.007_bib25","article-title":"PPAR\u03b1 activation preserves retinal vascular integrity in diabetes through modulation of oxidative stress and apoptosis","volume":"23","author":"Zhao","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcjd.2026.01.007_bib26","first-page":"10540","article-title":"Downregulation of fatty acid binding protein 4 alleviates lipid peroxidation and oxidative stress in diabetic retinopathy by regulating PPAR\u03b3-mediated ferroptosis","volume":"13","author":"Fan","year":"2022","journal-title":"Bioeng (Basel)"},{"key":"10.1016\/j.jcjd.2026.01.007_bib27","first-page":"316","article-title":"PPAR\u03b1 activation attenuates retinal inflammation and oxidative stress in diabetic rats","volume":"12","author":"Kim","year":"2023","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.jcjd.2026.01.007_bib28","article-title":"Fenofibrate inhibits VEGF-mediated retinal neovascularization and vascular leakage via AMPK activation in diabetic mice","volume":"198","author":"Shen","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jcjd.2026.01.007_bib29","article-title":"Association of peroxisome proliferator-activated receptors (PPARs) with diabetic retinopathy in human and animal models: Analysis of the literature and genome browsers","volume":"2020","author":"Tajsenk","year":"2020","journal-title":"PPAR Res"},{"key":"10.1016\/j.jcjd.2026.01.007_bib30","first-page":"496","article-title":"A novel concept of differences in pathogenic mechanism of diabetic retinopathy progression between type 2 diabetes mellitus patients differing in the PPAR\u03b3 genotype","volume":"5","author":"Natrus","year":"2020","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.jcjd.2026.01.007_bib31","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2147\/OPTH.S236637","article-title":"The evolving treatment of diabetic retinopathy","volume":"14","author":"Mansour","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jcjd.2026.01.007_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpath.2025.12.006","article-title":"Peroxisome proliferator-activated receptor \u03b1 deficiency induces vascular pathologies through endothelial senescence in diabetic retinopathy","author":"Xu","year":"2026","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jcjd.2026.01.007_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.788663","article-title":"Peroxisome proliferator-activated receptor \u03b1 activation protects retinal ganglion cells in ischemia-reperfusion retinas","volume":"8","author":"Yao","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.jcjd.2026.01.007_bib34","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1001\/jamaophthalmol.2022.0633","article-title":"Association of fenofibrate use with progression of diabetic retinopathy in a real-world population","volume":"140","author":"Meer","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjd.2026.01.007_bib35","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3390\/biomedicines8100433","article-title":"PPAR\u03b1 agonist oral therapy in diabetic retinopathy","volume":"8","author":"Tomita","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.jcjd.2026.01.007_bib36","first-page":"654","article-title":"Pemafibrate suppresses pathological retinal neovascularization via systemic FGF21 induction in mice","volume":"65","author":"Tomita","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.jcjd.2026.01.007_bib37","article-title":"Pemafibrate protects against diabetic retinal dysfunction and inflammation in murine models","volume":"160","author":"Matsui","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jcjd.2026.01.007_bib38","article-title":"Saroglitazar ameliorates oxidative stress and retinal vascular dysfunction in diabetic retinopathy model rats","volume":"919","author":"Patil","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jcjd.2026.01.007_bib39","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.3390\/healthcare13121437","article-title":"Endocrine and metabolic mechanisms linking obesity to type 2 diabetes: Implications for targeted therapy","volume":"13","author":"Allocca","year":"2025","journal-title":"Healthcare"},{"key":"10.1016\/j.jcjd.2026.01.007_bib40","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.biopha.2018.10.185","article-title":"A non-invasive, multi-target approach to treat diabetic retinopathy","volume":"109","author":"Julius","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jcjd.2026.01.007_bib41","first-page":"652","article-title":"Statin use and risk of progression to vision-threatening diabetic retinopathy: A population-based cohort study, 2002\u20132019","volume":"31","author":"Van der Meer","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jcjd.2026.01.007_bib42","first-page":"1280","article-title":"Polyphenol-loaded nonadevices as innovative therapeutic strategies for dry eye disease","volume":"14","author":"Conte","year":"2025","journal-title":"Adv Perspect Antioxid"},{"key":"10.1016\/j.jcjd.2026.01.007_bib43","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3390\/pharmaceutics17050599","article-title":"Ocular drug delivery: Emerging approaches and advances","volume":"17","author":"Gade","year":"2025","journal-title":"Pharmaceutics"}],"container-title":["Canadian Journal of Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499267126000304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499267126000304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:53:26Z","timestamp":1778889206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1499267126000304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1499267126000304"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjd.2026.01.007","relation":{},"ISSN":["1499-2671"],"issn-type":[{"value":"1499-2671","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peroxisome Proliferator-activated Receptors in Diabetic Retinopathy: Pathophysiologic Insights and Emerging Pharmacologic Strategies","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjd.2026.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Diabetes Canada.","name":"copyright","label":"Copyright"}]}}